Basic Information
| LncRNA/CircRNA Name | GAS5 |
| Synonyms | GAS5, NCRNA00030, SNHG2, ENST00000456293.5, GAS5-007 |
| Region | GRCh38_1:173863900-173868882 |
| Ensemble | ENSG00000234741 |
| Refseq | NR_002578 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | prostate cancer |
| ICD-0-3 | C61.9 |
| Methods | qPCR, RNAi, Western blot, Dual luciferase reporter assay, Cell proliferation assay, ISH etc. |
| Sample | prostate cancer tissues, cell lines (PC3, DU145, and LNCaP) |
| Expression Pattern | down-regulated |
| Function Description | The lncRNA GAS5 levels were reduced significantly in the PCa tissues and cell lines. A low exposure of lncRNA GAS5 caused AKT/mTOR signaling pathway activation in PC3 cells. In addition, over-exposure of lncRNA GAS5 was proven to significantly decelerate PCa cell progression in vitro and tumor growth in vivo through inactivating the AKT/mTOR signaling pathway.In this research, the exposure levels of the main components of the AKT/mTOR signaling pathway, including AKT, mTOR, and S6K1, all of which are tumorrelated genes, were assessed at total and at phosphorylation protein levels in vitro and in vivo. |
| Pubmed ID | 27743383 |
| Year | 2016 |
| Title | LncRNA GAS5 inhibits proliferation and progression of prostate cancer by targeting miR-103 through AKT/mTOR signaling pathway. |
External Links
| Links for GAS5 | GenBank HGNC NONCODE |
| Links for prostate cancer | OMIM COSMIC |